Uveitis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of uveitis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of uveitis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.
Clarivate Epidemiology’s uveitis forecast will answer the following questions:
- Of all people with uveitis, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of uveitis over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts the following uveitis patient populations:
- Diagnosed prevalent cases of uveitis.
- Diagnosed prevalent cases of infectious uveitis.
- Diagnosed prevalent cases of non-infectious uveitis.
- Diagnosed prevalent cases of anterior uveitis.
- Diagnosed prevalent cases of intermediate uveitis.
- Diagnosed prevalent cases of posterior uveitis.
- Diagnosed prevalent cases of panuveitis.
- Diagnosed prevalent cases of acute uveitis.
- Diagnosed prevalent cases of recurrent uveitis.
- Diagnosed prevalent cases of chronic uveitis.
Note: Coverage may vary by country.
Table of contents
- Uveitis - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Diagnosed Prevalence of Uveitis per 100,000 People of All Ages in 2021 and 2041
- Diagnosed Prevalence of Uveitis per 100,000 People of All Ages in 2021 and 2041
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Uveitis Over the Next 20 Years
- Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Uveitis Over the Next 20 Years
- Analysis of Diagnosed Prevalent Cases of Uveitis in 2021 by Etiology
- Analysis of Diagnosed Prevalent Cases of Uveitis in 2021 by Etiology
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Vivek Pathania, M.P.H., Epidemiologist, Epidemiology. Previously, he worked as a data manager in HIV Sentinel Surveillance (HSS). He completed his master’s in public health with a specialization in epidemiology from the Postgraduate Institute of Medical Education and Research in Chandigarh, India. He also holds a postgraduate degree in biotechnology.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.